🔗 Share this article

An underground market for unlicensed weight-loss medications is being driven by social media fitness personalities and sellers on communication apps, according to recent findings.

Investigational Drug Gaining Popularity Via Social Media

The experimental drug, which is still in research studies, is being promoted by online personalities for its alleged fat-burning properties. Viewers are urged to message these accounts privately for supplier links, while also receiving discount codes.

Thriving Commerce on Messaging Platforms

Separately, a flourishing market exists on messaging services, where communities with numerous of members share comparison photos, injection guides and claims of rapid UK delivery. Sellers promote the drug there before redirecting buyers to WhatsApp for purchases.

Learning About The Experimental Drug

Retatrutide is an experimental injection developed by US drugmaker Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could help individuals reduce up to 25% of their total weight. Referred to as the “triple G”, the drug is being promoted digitally as the successor to Ozempic.

Healthcare Professionals Express Worries

Nevertheless, doctors and chemists have warned that the sale of what remains an unapproved drug in the UK is a cause for concern and could result in users injecting substances of unknown origin.

Some experts said the popularity for the experimental drug could be connected to the increasing price of approved weight loss treatments such as Mounjaro.

Legal Status and Implementation

Marketing retatrutide on social media or messaging apps is prohibited in the United Kingdom, as it is an unapproved medication that must not be marketed or supplied for human use under the Human Medicines Regulations 2012.

Some content creators try to circumvent the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled drug, but advertising and distribution can still violate pharmaceutical, marketing, and consumer regulations, risking penalties, prosecution or imprisonment.

Platform Response and Material Removal

Based on the social media company, the service has taken down problematic content and prohibited related hashtags and query recommendations. The organization said it was dedicated to keeping the service secure and investing in enhancing compliance measures.

Digital Trading Operations

Investigations also found communities with up to nine thousand participants selling retatrutide using Telegram's built-in search feature, which operates like a public directory. Typing “retatrutide” instantly brings up groups with thousands of users, filled with photos of slimming results, positive reviews and step-by-step guides for mixing or administering at residence.

After moments of entering one community, a seller shared contact information, where the majority of purchases occur. The vendor sent an instruction manual and promised shipping within 48 hours. When asked whether the product was genuine, one vendor responded: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. Not one inquired about weight, health issues or previous experience.

Item Information and Costs

Within these communities, messages show black plastic parcels with Royal Mail stickers, claiming to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”

Customers can choose between powder vials, mixed at home with sterile water, or ready-to-use pens typically priced at 160 pounds for 20mg. When questioned how long a pen should be used, vendors give conflicting responses ranging from a few weeks to “depends on your body”.

Service Moderation and Safety Actions

A spokesperson for Telegram stated it regularly moderated harmful content on its platform including material that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Medical Expert Warnings

“People are administering substances they can’t verify. Although the science behind retatrutide is valid, these digital products may not include what they advertise,” said a pharmacy expert, the director of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of an online medical service linked the surge in interest to recent price rises for authorized weight-loss drugs such as Mounjaro. “With costs rising, individuals are turning to online platforms. But counterfeit treatments are highly dangerous. You cannot know what’s contained or whether the environment they were produced in was sterile,” she said.

Her team has already encountered patients harmed by personal administration from unverified suppliers. “We recognize the frustration, but purchasing from Telegram or communication platforms is taking chances with your health,” stated Wyllie. “These materials could be contaminated or incorrectly dosed.”

Producer Position

A representative from the pharmaceutical company said retatrutide was in phase 3 research studies and had not been reviewed or approved by any government authority anywhere in the world. “Therefore at this point no one can sell [it] for human use,” they explained, adding that any item “falsely representing itself as a company experimental substance not yet authorized … may subject users to potentially serious health risks”.